193 related articles for article (PubMed ID: 24804695)
21. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
[TBL] [Abstract][Full Text] [Related]
22. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
23. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P
J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502
[TBL] [Abstract][Full Text] [Related]
24. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
25. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.
Wittert G; Bracken K; Robledo KP; Grossmann M; Yeap BB; Handelsman DJ; Stuckey B; Conway A; Inder W; McLachlan R; Allan C; Jesudason D; Fui MNT; Hague W; Jenkins A; Daniel M; Gebski V; Keech A
Lancet Diabetes Endocrinol; 2021 Jan; 9(1):32-45. PubMed ID: 33338415
[TBL] [Abstract][Full Text] [Related]
26. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
Feig DS; Donovan LE; Zinman B; Sanchez JJ; Asztalos E; Ryan EA; Fantus IG; Hutton E; Armson AB; Lipscombe LL; Simmons D; Barrett JFR; Karanicolas PJ; Tobin S; McIntyre HD; Tian SY; Tomlinson G; Murphy KE;
Lancet Diabetes Endocrinol; 2020 Oct; 8(10):834-844. PubMed ID: 32946820
[TBL] [Abstract][Full Text] [Related]
27. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
Mudaliar S; Henry RR; Boden G; Smith S; Chalamandaris AG; Duchesne D; Iqbal N; List J
Diabetes Technol Ther; 2014 Mar; 16(3):137-44. PubMed ID: 24237386
[TBL] [Abstract][Full Text] [Related]
28. MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial.
Magnussen LV; Andersen PE; Diaz A; Ostojic J; Højlund K; Hougaard DM; Christensen AN; Nielsen TL; Andersen M
Eur J Endocrinol; 2017 Aug; 177(2):157-168. PubMed ID: 28522646
[TBL] [Abstract][Full Text] [Related]
29. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
Libman IM; Miller KM; DiMeglio LA; Bethin KE; Katz ML; Shah A; Simmons JH; Haller MJ; Raman S; Tamborlane WV; Coffey JK; Saenz AM; Beck RW; Nadeau KJ;
JAMA; 2015 Dec; 314(21):2241-50. PubMed ID: 26624824
[TBL] [Abstract][Full Text] [Related]
30. Comment on Gianatti et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care 2014;37:2098-2107.
Jones TH
Diabetes Care; 2014 Dec; 37(12):e267-8. PubMed ID: 25414402
[No Abstract] [Full Text] [Related]
31. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B
Digenio A; Pham NC; Watts LM; Morgan ES; Jung SW; Baker BF; Geary RS; Bhanot S
Diabetes Care; 2018 Apr; 41(4):807-814. PubMed ID: 29439147
[TBL] [Abstract][Full Text] [Related]
32. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial.
Kahl S; Gancheva S; Straßburger K; Herder C; Machann J; Katsuyama H; Kabisch S; Henkel E; Kopf S; Lagerpusch M; Kantartzis K; Kupriyanova Y; Markgraf D; van Gemert T; Knebel B; Wolkersdorfer MF; Kuss O; Hwang JH; Bornstein SR; Kasperk C; Stefan N; Pfeiffer A; Birkenfeld AL; Roden M
Diabetes Care; 2020 Feb; 43(2):298-305. PubMed ID: 31540903
[TBL] [Abstract][Full Text] [Related]
33. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
[TBL] [Abstract][Full Text] [Related]
34. Response to comment on Gianatti et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care 2014;37:2098-2107.
Gianatti EJ; Hoermann R; Grossmann M
Diabetes Care; 2014 Dec; 37(12):e269. PubMed ID: 25414403
[No Abstract] [Full Text] [Related]
35. Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial.
Ng Tang Fui M; Hoermann R; Prendergast LA; Zajac JD; Grossmann M
Int J Obes (Lond); 2017 Mar; 41(3):420-426. PubMed ID: 28028318
[TBL] [Abstract][Full Text] [Related]
36. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
[TBL] [Abstract][Full Text] [Related]
37. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
38. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
Yale JF; Xie J; Sherman SE; Garceau C
Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
[TBL] [Abstract][Full Text] [Related]
39. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
Yki-Järvinen H; Rosenstock J; Durán-Garcia S; Pinnetti S; Bhattacharya S; Thiemann S; Patel S; Woerle HJ
Diabetes Care; 2013 Dec; 36(12):3875-81. PubMed ID: 24062327
[TBL] [Abstract][Full Text] [Related]
40. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
